IL4R and eosinophilic esophagitis: However, an IL-4R-targeted treatment that is already in use for other atopic conditions, dupilumab, was recently approved by the Food and Drug Administration for the treatment of EoE, resulting in both histologic remission and symptom improvement (Table 1) [134].